Michael Tusche, Ph.D., M.B.A

Overview

Michael Tusche holds a Ph.D. in Immunology from the University of Toronto [10] and an MBA from the University of Toronto's Rotman School of Management [11], along with a Bachelor of Science from the University of Victoria [12]. Tusche currently serves as an Operating Partner at Catalio Capital Management [1][2] and as Board Director at Nirsum Labs [3], where Tusche previously held the position of Chief Scientific Officer and Co-Founder from April 2017 to December 2019 [8]. Tusche's career has included roles as Interim CEO of Rhapsogen, Inc. [4], CEO of 3io Therapeutics [5], Co-CEO and Board Director at Treadwell Therapeutics, Inc. [6], Partner at TIO Bioventures [7], and Senior Healthcare Analyst at Mountain Brook Capital [9].

Career history

1. Operating PartnerFeb 2025 to presentCatalio Capital Management
2. NLBoard DirectorOct 2024 to presentNirsum Labs
3. RIInterim CEOFeb 2025 to Jan 2026Rhapsogen, Inc.
4. 3TCEOSep 2024 to Sep 20253io Therapeutics
5. TTCo-CEO | Board DirectorJan 2020 to Dec 2023Treadwell Therapeutics, Inc.
6. TBPartnerJan 2020 to Dec 2023TIO Bioventures
7. NLCSO | Co-FounderApr 2017 to Dec 2019Nirsum Labs
8. MBSenior Healthcare AnalystSep 2014 to Dec 2019Mountain Brook Capital

Education

1. Ph.D. (Immunology)University of Toronto
2. MBAUniversity of Toronto·Rotman School of Management
3. UOBachelor of Science (B.Sc.)University of Victoria